Evaluate Efficacy and Safety of XELOX in Potentially Resectable Liver Metastasis From Colorectal Cancer(CRC)

Launched by GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL · Oct 18, 2009

Keywords

ClinConnect Summary

To investigate the progression free survival (PFS) advantage of Xeloda plus oxaliplatin in the peri-operative treatment of potential resectable metastatic colorectal cancer

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age of 18 and 65
• • Histologically confirmed colorectal cancer and two methords of imaging detection confirmed liver metastasis
• • Potentially curable by resection, as determined by a surgeon with hepatic surgery expertise
• • No evidence of extrahepatic disease by chest x-ray or CT scan of the chest, abdomen, and pelvis
• • Patients with adequate hepative, renal and bone marrow function
• • Signed written informed consent
• Exclusion Criteria:
• • Pregnant or nursing patients (fertile patients must use effective contraception)
• • Other malignancy within the past 5 years except completely resected nonmelanoma skin cancer or carcinoma in situ of the cervix
• • Preexisting grade 2 or greater peripheral neuropathy
• • Concurrent uncontrolled illness
• • Ongoing or active infection
• • Psychiatric illness or social situation that would preclude study compliance
• • Less than 6 months since prior adjuvant fluorouracil-based chemotherapy
• • Prior chemotherapy for liver metastasis
• • Prior oxaliplatin for colorectal cancer
• • Prior or concurrent hepatic artery infusion chemotherapy for metastatic disease
• • Prior or concurrent radiotherapy for metastatic disease
• • Prior or concurrent radiofrequency ablation for metastatic disease
• • concurrent treatment with any other anti-cancer therapy.